JY
TARS icon

Jeff Yass’s Tarsus Pharmaceuticals TARS Stock Holding History

Jeff Yass’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.1M Buy
33,290
+16,655
+100% +$1.06M ﹤0.01% 6383
2026
Q1 		$1.17M Buy
16,635
+7,213
+77% +$504K ﹤0.01% 7476
2025
Q4 		$771K Buy
+9,422
New +$704K ﹤0.01% 7780
2025
Q3 		– Sell
-52,334
Closed -$2.58M – 13844
2025
Q2 		$2.12M Sell
52,334
-8,523
-14% -$384K ﹤0.01% 5660
2025
Q1 		$3.13M Sell
60,857
-3,266
-5% -$161K ﹤0.01% 4571
2024
Q4 		$3.55M Buy
64,123
+51,669
+415% +$2.35M ﹤0.01% 4149
2024
Q3 		$410K Buy
+12,454
New +$350K ﹤0.01% 8948
2024
Q2 		– Sell
-60,994
Closed -$2.05M – 13214
2024
Q1 		$2.22M Sell
60,994
-30,429
-33% -$895K ﹤0.01% 5083
2023
Q4 		$1.85M Buy
+91,423
New +$1.53M ﹤0.01% 5533
2023
Q3 		– Sell
-32,435
Closed -$574K – 12954
2023
Q2 		$586K Buy
+32,435
New +$516K ﹤0.01% 7938
2022
Q4 		– Sell
-14,257
Closed -$244K – 13640
2022
Q3 		$244K Buy
+14,257
New +$226K ﹤0.01% 10334

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jeff Yass's TARS Position: Q2 2026 in Review

Jeff Yass increased its Tarsus Pharmaceuticals (TARS) stake by 100% in Q2 2026, buying an estimated $1.06M and bringing the position to 33,290 shares worth $2.1M. The position accounts for ﹤0.01% of the portfolio, ranked #6383.

Jeff Yass first reported a position in TARS in Q3 2022 and has held it in 11 quarters since. The position peaked at $3.55M in Q4 2024. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Jeff Yass held 33,290 shares of Tarsus Pharmaceuticals worth $2.1M as of Q2 2026.
  • Jeff Yass bought 16,655 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $1.06M.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #6383 holding.
  • Jeff Yass first reported a position in Tarsus Pharmaceuticals in Q3 2022 and has held it in 11 quarters since.
  • Jeff Yass's Tarsus Pharmaceuticals position peaked at $3.55M in Q4 2024.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.